Abstract
Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).
| Original language | English |
|---|---|
| Pages (from-to) | 484-486 |
| Number of pages | 3 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 66 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 Aug 15 |
Keywords
- Adenosine triphosphate-binding cassette transporter G2
- Antiretroviral therapy
- Blood-cerebrospinal fluid barrier
- Cerebrospinal fluid concentrations
- Raltegravir
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants'. Together they form a unique fingerprint.
Cite this
Tsuchiya, K., Hayashida, T., Hamada, A., Kato, S., Oka, S., & Gatanaga, H. (2014). Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants. Journal of Acquired Immune Deficiency Syndromes, 66(5), 484-486. https://doi.org/10.1097/QAI.0000000000000222